Literature DB >> 15330898

Risk stratification of Barrett's esophagus: updated prospective multivariate analysis.

Allan P Weston1, Prateek Sharma, Sharad Mathur, Sushanta Banerjee, A Khatib Jafri, Rachel Cherian, Douglas McGregor, Ruth S Hassanein, Matthew Hall.   

Abstract

OBJECTIVES: Prospective evaluation of Barrett's esophagus (BE) in order to determine what demographic, endoscopic, and histologic features are predictive of the prevalence and incidence of Barrett's high-grade dysplasia (HGD) and adenocarcinoma (Ca).
METHODS: Newly diagnosed BE patients were entered into and followed in a standardized surveillance protocol. The following features were examined using either forward, stepwise multiple regression analysis, or Cox proportional hazards to determine their ability to predict the presence of HGD or Ca at index BE diagnosis as well as their ability to predict progression of BE during follow-up: age, race, gender, length of BE in cm, size of a hiatal hernia, severity of dysplasia at index diagnosis as well as during surveillance, gastric Helicobacter pylori infection status, and type of medical acid-reflux treatment.
RESULTS: A total of 550 patients were diagnosed with BE over the study period. Stepwise multiple regression analysis showed three factors significantly associated with index diagnosis of HGD or Ca: hiatal hernia (larger size), Barrett's length (longer length), and absence of H. pylori infection. Three hundred and twenty-four BE entered the surveillance protocol. Cox proportional hazards models revealed a significant and independent association for five factors predictive of the time to progression of BE: presence of dysplasia at index diagnosis (p < 0.001), severity of dysplasia during surveillance (p < 0.001), length of Barrett's epithelium (p= 0.012), size of hiatal hernia (p= 0.006), and gastric H. pylori infection status (p= 0.023).
CONCLUSIONS: Endoscopic and histologic features of BE at initial diagnosis are predictive of index HGD and cancer as well as with risk of BE progression.

Entities:  

Mesh:

Year:  2004        PMID: 15330898     DOI: 10.1111/j.1572-0241.2004.30426.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  42 in total

1.  Increased expression of VEGF, COX-2, and Ki-67 in Barrett's esophagus: does the length matter?

Authors:  Evanthia Zampeli; George Karamanolis; George Morfopoulos; Elias Xirouchakis; Vasiliki Kalampoki; Spyros Michopoulos; Sotiria Savva; Vasilios Tzias; Irene Zouboulis-Vafiadis; Dimitrios Kamberoglou; Spiros D Ladas
Journal:  Dig Dis Sci       Date:  2011-12-07       Impact factor: 3.199

Review 2.  [Barrett's esophagus. An update].

Authors:  G B Baretton; D E Aust
Journal:  Pathologe       Date:  2012-02       Impact factor: 1.011

3.  Quality indicators for the management of Barrett's esophagus, dysplasia, and esophageal adenocarcinoma: international consensus recommendations from the American Gastroenterological Association Symposium.

Authors:  Prateek Sharma; David A Katzka; Neil Gupta; Jaffer Ajani; Navtej Buttar; Amitabh Chak; Douglas Corley; Hashem El-Serag; Gary W Falk; Rebecca Fitzgerald; John Goldblum; Frank Gress; David H Ilson; John M Inadomi; Ernest J Kuipers; John P Lynch; Frank McKeon; David Metz; Pankaj J Pasricha; Oliver Pech; Richard Peek; Jeffrey H Peters; Alessandro Repici; Stefan Seewald; Nicholas J Shaheen; Rhonda F Souza; Stuart J Spechler; Prashanth Vennalaganti; Kenneth Wang
Journal:  Gastroenterology       Date:  2015-08-19       Impact factor: 22.682

Review 4.  Barrett's Esophagus: A Comprehensive and Contemporary Review for Pathologists.

Authors:  Bita V Naini; Rhonda F Souza; Robert D Odze
Journal:  Am J Surg Pathol       Date:  2016-05       Impact factor: 6.394

5.  Ablating Barrett's metaplastic epithelium: are the techniques ready for clinical use?

Authors:  J J G H M Bergman; P Fockens
Journal:  Gut       Date:  2006-09       Impact factor: 23.059

6.  The risk of oesophageal adenocarcinoma in a prospectively recruited Barrett's oesophagus cohort.

Authors:  B T Theron; H Padmanabhan; H Aladin; P Smith; E Campbell; P Nightingale; B T Cooper; N J Trudgill
Journal:  United European Gastroenterol J       Date:  2016-02-19       Impact factor: 4.623

7.  Predictive factors of coexisting cancer in Barrett's high-grade dysplasia.

Authors:  C Tharavej; J A Hagen; J H Peters; G Portale; J Lipham; S R DeMeester; C G Bremner; T R DeMeester
Journal:  Surg Endosc       Date:  2006-01-25       Impact factor: 4.584

Review 8.  Management of high-grade dysplasia.

Authors:  Francesco Palazzo; Piero M Fisichella; Marco G Patti
Journal:  Curr Gastroenterol Rep       Date:  2008-06

9.  Incidence and predictors of adenocarcinoma following endoscopic ablation of Barrett's esophagus.

Authors:  Kazuhiro Yasuda; Sung Eun Choi; Norman S Nishioka; David W Rattner; William P Puricelli; Angela C Tramontano; Seigo Kitano; Chin Hur
Journal:  Dig Dis Sci       Date:  2014-01-07       Impact factor: 3.199

10.  Gallstones increase the prevalence of Barrett's esophagus.

Authors:  Juntaro Matsuzaki; Hidekazu Suzuki; Keiko Asakura; Yoshimasa Saito; Kenro Hirata; Toru Takebayashi; Toshifumi Hibi
Journal:  J Gastroenterol       Date:  2009-11-12       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.